TITLE

Copper Deficiency Myelopathy (Human Swayback)

AUTHOR(S)
Kumar, Neeraj
PUB. DATE
October 2006
SOURCE
Mayo Clinic Proceedings;Oct2006, Vol. 81 Issue 10, p1371
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The hematologic manifestations of copper deficiency are well known and include anemia and neutropenia. In the past few years, the neurological manifestations of acquired copper deficiency in humans has been recognized, the most common being a myelopathy presenting with a spastic gait and prominent sensory ataxia. The known causes of acquired copper deficiency include prior gastric surgery, excessive zinc ingestion, and malabsorption; however, often the cause is unclear. Hyperzincemia may be present even in the absence of exogenous zinc ingestion. The clinical features and neuroimaging findings are similar to the subacute combined degeneration seen in patients with vitamin B12 deficiency. Copper and vitamin B12 deficiency may coexist. The neurological syndrome may be present without the hematologic manifestations. Copper supplementation resolves the anemia and neutropenia promptly and completely and may prevent the neurological deterioration. Improvement, when it occurs, is often subjective and preferentially Involves sensory symptoms. This article describes patients with copper deficiency myelopathy seen at the Mayo Clinic in Rochester, Minn, and reviews the literature on neurological manifestations of acquired copper deficiency in humans.
ACCESSION #
23272670

 

Related Articles

  • Anemia and Neutropenia Caused by Copper Deficiency.  // Annals of Internal Medicine;Apr74, Vol. 80 Issue 4, p470 

    Illustrates unique circumstances that resulted in the development of copper deficiency, manifested by anemia and neutropenia in an adult woman and by neutropenia alone in an adolescent girl. Effects of copper deficiency; Possible mechanisms causing the anemia and neutropenia; Importance of...

  • UNDERSTANDING THE TREATMENT OF NEUTROPENIC FEVERS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. Adams, Laura // Oncology Nursing Forum;Mar2006, Vol. 33 Issue 2, p428 

    Neutropenia is a common toxicity of therapy for hematologic malignancies. It is defined as <500 neutrophils/mm³ or <1,000 neutrophils/ mm³ with a predicted decrease to <500 neutrophils/mm³. Infections occurring during neutropenia are a leading cause of morbidity and mortality. The...

  • Zinc.  // Reactions Weekly;10/25/2008, Issue 1225, p27 

    The article describes the case of an 81-year-old man who developed zinc-induced hypocupraemia to anaemia and neutropenia while receiving zinc supplementation. The man presented with exercise intolerance and was treated with darbepoetin with no improvement in his anaemia. His haemoglobin level...

  • Copper deficiency myelopathy. Jaiser, Stephan R.; Winston, Gavin P. // Journal of Neurology;Jun2010, Vol. 257 Issue 6, p869 

    Acquired copper deficiency has been recognised as a rare cause of anaemia and neutropenia for over half a century. Copper deficiency myelopathy (CDM) was only described within the last decade, and represents a treatable cause of non-compressive myelopathy which closely mimics subacute combined...

  • Myeloneuropathy due to copper deficiency: clinical and MRI findings after copper supplementation. Bolamperti, Laura; Leone, Maurizio A.; Stecco, Alessandro; Reggiani, Monica; Pirisi, Mario; Carriero, Alessandro; Monaco, Francesco // Neurological Sciences;Dec2009, Vol. 30 Issue 6, p521 

    Acquired copper deficiency constitutes an under-recognised cause of myelopathy. Aim of the study was to describe the clinical and imaging features at admission and after copper supplementation of a patient with acquired copper deficiency myeloneuropathy. A 73-year-old woman presented with...

  • PERSPECTIVE: ECULIZUMAB. Boxer, Laurence // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug eculizumab which he believes has the potential to change practice.

  • PERSPECTIVE: ECULIZUMAB. Moake, Joel L. // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug eculizumab which he believes has the potential to change practice.

  • PERSPECTIVE: BRENTUXIMAB VEDOTIN. Cabanillas, Fernando // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug brentuximab vedotin which he believes has the potential to change practice.

  • PERSPECTIVE: CARFILZOMIB. Lohr, Lisa K. // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p76 

    The author presents his views about hematology drug carfilzomib which she believes has the potential to change practice.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics